key: cord-0784427-gkqubmkp authors: Wang, Jiahao; Lyu, Yun; Zhang, Haijun; Jing, Rize; Lai, Xiaozhen; Feng, Huangyufei; Deloria Knoll, Maria; Fang, Hai title: Willingness to Pay and Financing Preferences for COVID-19 Vaccination in China date: 2021-02-27 journal: Vaccine DOI: 10.1016/j.vaccine.2021.02.060 sha: 548bce6932d2e98489ffc99ff199ff62ed654345 doc_id: 784427 cord_uid: gkqubmkp Background The COVID-19 pandemic has caused significant diseases and economic burdens in the world. Vaccines are often considered as a cost-effective way to prevent and control infectious diseases, and the research and development of COVID-19 vaccines have been progressing unprecedently. It is needed to understand individuals’ willingness to pay (WTP) among general population, which provides information about social demand, access and financing for future COVID-19 vaccination. Objective To investigate individuals’ WTP and financing mechanism preference for COVID-19 vaccination during the pandemic period in China. Methods During March 1-18, 2020, we conducted a network stratified random sampling survey with 2058 respondents in China. The survey questionnaires included out-of-pocket WTP, financing mechanism preference as well as basic characteristics of the respondents; risk perception and impact of the COVID-19 pandemic; attitude for future COVID-19 vaccination. Multivariable Tobit regression was used to determine impact factors for respondents’ out-of-pocket WTP. Results The individuals’ mean out-of-pocket WTP for full COVID-19 vaccination was CNY 254 (USD 36.8) with median of CNY 100 (USD 14.5). Most respondents believed that governments (90.9%) and health insurance (80.0%) needed to pay for some or full portions of COVID-19 vaccination, although 84.3% stated that individuals needed to pay. Annual family income, employee size in the workplace, and whether considering the COVID-19 pandemic in China in a declining trend affected respondents’ WTP significantly. Conclusion The findings demonstrated the individuals’ WTP for COVID-19 vaccination in China and their preferences for financing sources from individuals, governments and health insurance. And to suggest an effective and optimal financing strategy, the public health perspective with equal access to COVID-19 vaccination should be prioritized to ensure a high vaccination rate. The coronavirus disease 2019 (COVID- 19) pandemic has been causing severe diseases and economic burdens around the world [1, 2] . As there are no effective treatments or drugs against COVID-19 at the current stage, vaccination has been considered to be of great importance to combat the COVID-19 pandemic [3] [4] [5] [6] . Governments, research institutes, pharmaceuticals, and organizations around the world are working together to accelerate the COVID-19 vaccination for the public, by making full effort and preparation in the progress of research, development, logistics and manufacturing [4, 7] . Although COVID-19 vaccines seem promising in the supply side, in the demand side the unknown about the perception, assessment or valuation for future COVID-19 vaccination by the public so far may hinder the successful establishment of future vaccination campaigns. Vaccination cost is predicted to be very high, including expenses for vaccines, distribution, administration, adverse events following immunization (AEFI), and others [8, 9] . To control and prevent the current COVID-19 pandemic and future outbreaks, vaccination strategies designed to reach a high vaccination coverage should address problems in terms of vaccination accessibility and financial affordability [10] . To understand individuals' willingness to pay (WTP) among general population would provide relevant information about social demand, access and financing for future COVID-19 vaccination. The willingness to pay (WTP) for vaccination is a monetary measure of the public's preference and perception for vaccination, reflecting the tradeoff between the benefits of the vaccination from preventing infectious diseases and the personal economic cost in public [11] [12] [13] . Previous studies have found various factors affecting WTP of vaccination, such as the type of diseases, social-economic characteristics, previous history of vaccination, the knowledge, attitudes and practices about vaccination, and recommendations of peers or doctors [12] [13] [14] [15] [16] . Lessons from the 2009 H1N1 pandemic Influenza has stressed that the shortcoming of financial affordability and distributing for enough vaccines in a timely basis could lead to the failure of making a good preparedness and response for pandemics, especially in low-andmiddle income countries. This reflected the importance of proper pricing and financing mechanisms for pandemic vaccination [17, 18] . Based on the immunization financing mechanisms in China, which divided vaccines into Expanded Program on Immunization (EPI) vaccines and non-EPI vaccines, EPI vaccines are fully covered by the government tax, while non-EPI vaccines are completely paid out of pocket without any subsidy or insurance, resulting in very low coverage rates of non-EPI vaccines in China, such as vaccines against influenza [12, 19, 20] . Increasing the acceptance and coverage rate for vaccines, especially pandemic vaccines, remains a challenge in China [21] . The significant vaccine production costs, vaccination costs and other indirect costs in the future will inevitably lead to a huge economic burden on individuals and governments in China. This suggests that it is not feasible to rely on individual's out-of-pocket payment for establishing the financing mechanism of COVID-19 vaccination in China. The financing for COVID-19 vaccination would be of great importance and complicity, as many factors should be taken into consideration, including the public health effect (e.g. protecting population, achieving optimal coverage and equity in health outcomes), financing sources and fiscal capacity, manufacturing cost and capacity, perception of the public, policy makers and stakeholders, etc [22] [23] [24] [25] [26] . It may be an ideal strategy to make vaccination free of charge for individuals, if it is feasible. And the public WTP and financing perception for future COVID-19 vaccination would provide references from the demand side in the pricing, marketing and financing of the vaccines. During the outbreak period of COVID-19, we aimed to investigate and evaluate individuals' WTP and financing perception for future COVID-19 vaccination in China in order to prepare for its public availability. By considering the comprehensive cost of vaccination and the economic burden, we discussed feasible financing strategies for future COVID-19 vaccination in China. During March 1-18, 2020, we conducted a cross-sectional anonymous survey on the largest online survey platform in China, Wen Juan Xing (Changsha Ranxing Information Technology Co., Ltd., Hunan, China). Wen Juan Xing, equivalent to Qualtrics, SurveyMonkey or CloudResearch, provides online questionnaire design and survey functions for enterprises, research institutions and individuals. Its sample database consists of over 2.6 million respondents with confirmed personal information, allowing for an authentic, diverse and representative sample. The target population of the survey was adults living in Mainland China; thus, we adopted a random sample procedure stratified by ages and locations to match Chinese adults in the Wen Juan Xing sample database. Chinese respondents who aged 18 years and above and resided in Mainland China in the Wen Juan Xing sample database were eligible to participate in the survey. In general, 2100 respondents were randomly selected, and the final sample consisted of 2058 respondents after excluding incomplete and invalid questionnaires by quality control and manual check procedures. The self-administered questionnaire was designed based on previous studies and frameworks on assessing WTP for vaccination against newly emerging infectious diseases such as H1N1 and Ebola [12-14, 27, 28] . The questionnaire included: (1) Respondents' sociodemographic characteristics;(2) Risk perception and impact of the COVID-19 pandemic; (3) Attitude for future COVID-19 vaccination; (4) The acceptable out-of-pocket WTP, preferences of financing mechanism and self-paid proportion for COVID-19 vaccination. The main outcome measures were the out-of-pocket WTP and financing mechanism perception for COVID-19 vaccination, if COVID-19 vaccines could be licensed and available in the future. Respondents were asked whether they thought that individuals, governments or health insurance need to pay for COVID-19 vaccination and if yes, whether to pay partially or fully. And respondents were further asked to report their preferred self- [29] . Starting-point bias existed in the bidding game, while OE format might be difficult to answer, and PS format scale itself might influence the subjects' decisions [29] . Given the methods available online and to reduce the bias by methods, we adopted two types of questions to evaluated the WTP for COVID-19 vaccination, the OE format and the PS format. The monetary amount used in the questionnaire was Chinese yuan (CNY). Participants were asked "What is the maximum amount that you are willing to pay for COVID-19 vaccination (receiving all doses of the series as the vaccination schedule), if you want to get vaccinated?" according to the definition and question frame of the WTP [30] . The choices provided for respondents in the PS were: "refused vaccination", "willing to get vaccinated if free", "CNY 10", "CNY 50", "CNY 100", "CNY 200", "CNY 500", "willing to pay for any price". The price range was set to cover private market prices of basically all adult vaccines in China. The OE question asked respondents to report WTP by themselves. The PS format question was deployed in the middle of the questionnaire, and the OE question was set at the end of the questionnaire to double check the WTP value from the PS question. The setting of the questions about the WTP and self-paid proportion was based on the considerations of the two ways, copay and coinsurance, which were adopted in the payment for vaccinations, and that there are various possibilities in financing for the COVID-19 vaccination [31, 32] .Most questions were treated as categorical variables except for the OE format of WTP and self-paid proportion, and self-reported questions were assessed on a fivepoint Likert scale, such as health status, risk perception of the COVID-19 pandemic. We present the distribution of the WTP value and the self-paid proportion from the OE format. The financing mechanism perceptions were described as constituent ratio variables. Descriptive statistics were used to present baseline characteristics, the risk perception, impact of the pandemic and attitude for future COVID-19 vaccination. We provided an equivalence of the monetary amount in US Dollars (USD) at an exchange rate of 6.9 yuan per dollar in 2020. We conducted a multivariate Tobit regression to identify impact factors on the WTP, with coefficient, standard errors (SE) and p-value reported, as the OE WTP measures were truncated. Respondents who refused to vaccinate were excluded when calculating the WTP and conducting the regression, as suggested by the previous studies [12-14, 27, 28] . We conducted a sensitivity analysis by providing the distribution of the WTP value from the PS format for reference and minimizing the bias on WTP valuations. Analyses were performed using STATA 16.0 with two-tailed tests. In total, 2058 out of 2100 respondents completed the questionnaires during March 1-18, 2020, with a response rate of 98.0%. Respondents were located in all 31 provincial administrative regions of Mainland China (Appendix Table A1 ). The distribution of respondents' age is 23.1% in 18~25 years old, 19 . During the survey, 74.7% of respondents stated that there were confirmed or suspected cases in the county in which they lived at that time and 55.2% lacked protective equipment. But in this pandemic period, only 12.2% perceived the risk of being infected personally with COVID-19 as high or very high, and the majority (69.8%) believed that the COVID-19 pandemic in China was in a declining trend (in March 2020 when the survey was conducted) (Appendix Table A2 ). Table 1 presents the respondents' financing mechanism preference for COVID-19 vaccination. A portion (15.7%) of respondents believed that individuals did not need to pay out of pocket of the COVID-19 vaccination costs, and only few people (6.4%) stated that individuals needed to pay fully for COVID-19 vaccination out of pocket. 77.9% of the respondents thought that individuals needed to pay for a portion of COVID-19 vaccination costs. In contrast, most respondents believed that governments and health insurance needed to pay for some or all portions of COVID-19 vaccination costs, accounting for 90.9% and 80.0% respectively. [ Table 1 ] Table 2 presents the distribution of WTP by OE format and self-paid proportion for COVID-19 vaccination. Among the total 2058 respondents, 1879 (91.3%) would accept future COVID-19 vaccination, and 1847 (89.7%) were willing to pay at the price of CNY 10 and above. The mean WTP for the COVID-19 vaccination in the OE format was CNY 254 (SD=677), and the median was CNY 100. The maximum WTP in the OE question was CNY 10,000. With some respondents reported much higher WTP value compared with that of the majority (e.g. CNY 1000 and above), the distribution of WTP data showed a right skewed trend and the mean WTP was higher than the median. More respondents had lower willingness to pay for COVID-19 vaccination than the mean. The mean self-paid proportion for COVID-19 vaccination was 45% (SD=22), with the median about 47%. [ Table 2 ] Table 3 shows the distribution of the WTP value from the PS format. 31.1% of the respondents were willing to pay for COVID-19 vaccination at the price of CNY 50 or less. In addition, the proportions of respondents who were willing to pay at the price of CNY 100 and 200 accounted for 27.0% and 18.7%, respectively, which were similar with those in the OE format in Table 2 . The WTP in the OE format and PS format were fairly consistent and robust. [ Table 3 ] The results of the multivariate Tobit regression are presented in Table 4 by estimating the WTP in the OE format on influencing factors. The annual family income and the employee size in the workplace were positively correlated with WTP. Compared with respondents whose annual family incomes were below CNY 50,000, those with annual family incomes of CNY 150,000 ~200,000, 200,000 ~300,000, 300,000 and above had CNY 68, 66 and 136 higher WTP, respectively. Respondents who worked in the workplaces with the size of 10~29, 30~100, 100~300, 300 and above had higher WTP of CNY 54, 47, 46 and 66 than those who worked in the workplace with less than 10 employees. Respondents who considered the pandemic COVID-19 in China in a declining trend had CNY 28 lower WTP than that of those who did not have the same perception. [ Table 4 ] Our study reports the willingness to pay (WTP) and financing preference for future COVID-19 vaccination among the Chinese population sampled during the COVID-19 pandemic. Most respondents were willing to pay for a portion of vaccination costs, reflecting the strong demand for COVID-19 vaccination to control and prevent the COVID-19 pandemic. The average out-of-pocket WTP for full COVID-19 vaccination was CNY 254 (USD 36.8), while the median was declined to CNY 100 (USD 14.5). Regarding the financing mechanism preference, most respondents believed that governments and health insurance both needed to pay partially or full for COVID-19 vaccination. The use of two approaches of OE format and PS format provided a comprehensive result in evaluating the WTP. In general, we found that most respondents were willing to pay out of pocket for COVID-19 vaccination by the Chinese public. More than 30% of the respondents were willing to pay CNY 50 or less and the vast majority (80.1%) were willing to pay CNY 200 or less. The PS format also showed that the majority (65.8%) were willing [35, 36] . When measured in purchasing parity power equivalents, the mean WTP of our result was USD 60.8, and it was about USD 79.7 in Malaysia and USD 269.7 in Chile [37] . So the mean WTP in China was roughly at the same level with that in Malaysia, but much lower than that in Chile. This might be explained by the context-specific factors such as perception of the severity and risk about diseases, which varied across disease types or locations [12, 27, 35, 36] . COVID-19 has demonstrated higher severity in terms of transmissibility and mortality than seasonal influenza, so respondents were willing to pay more for COVID-19 vaccination [12, 38, 39] . While the perceived risk of getting sick by COVID-19 was 99.1% among Chile population, only a small portion (12.2%) of the respondents in China perceived a high or very high level of risk due to the effective measures and public health interventions China has taken to control the transmission of COVID-19 since the outbreak [35, 40, 41] . Therefore, the WTP from our study was lower than that in Chile [35] . Some factors were found to have an impact on the WTP of respondents. Respondents with higher annual family incomes were willing to pay more for COVID-19 vaccination substantially, which was consistent with previous findings that the economic factor was reported as the main factor affecting the WTP and the acceptance of self-paid vaccination in China and other low-and-middle-income countries [11, 12, 42] . Respondents who worked in the workplace with more employees had higher WTP, while those who considered the COVID-19 pandemic in China in a declining trend had CNY 28 less WTP, both reflecting the effects of disease threat appraisal on WTP based on the Protection Motivation Theory [12, 27] . We found that the WTP for COVID-19 vaccination did not vary much by regions after other variables was controlled in the regression, such as factors of socio-economic, risk perception and pandemic impact. This might be due to the fact that most infected cases and deaths in China were in one province: Hubei province in the central region, and other provinces and counties had very few cases and deaths [43] . In addition to the socio-economic factors, some of the vaccine characteristics would also affect the WTP for COVID-19 vaccination as reported by studies of other countries [44, 45] . For example, people in Australia would be willing to pay USD 41, USD 34 and USD 23 to reduce waiting time of the vaccination by 1 month, reduce the severe reactions rate by 1/10,000, and increase the vaccine effectiveness, respectively, indicating the relative importance of vaccine characteristics [44] . While in Ecuador, only the protection duration was found to influence individuals WTP while the vaccine efficacy was not [45] . By July 2020, the direct medical treatment expenses for confirmed and suspected COVID-19 patients in China reached CNY 1.847 billion (USD 0.268 billion), of which 67% were paid by health insurance and the rests were paid by governments with fiscal funding [46] . Over 100 million Chinese people had taken COVID-19 nucleic acid amplification testing (NAT), with the total testing cost over CNY 12 billion [47] . By further considering the enormous economic loss that the COVID-19 pandemic has affected on the national economic growth, it is likely that COVID-19 vaccination is cost-effective if it has high vaccine effectiveness, long immunity duration, and low side-effects. As large investment has been put into the development of COVID-19 vaccines and the future manufacture may apply with high technology such as recombinant DNA technology, the price of the COVID-19 vaccine might be more expensive than traditional non-EPI vaccines in China [33, 48, 49] . Other operational activities and logistics also account for a large amount in the total vaccination cost, including remuneration, cold chain, surveillance, publicity, training, supervision [20] . Therefore, appropriate financing strategies for future COVID- More importantly, the COVID-19 vaccination strategies, including the financing, should take various aspects of factors into account, especially the public health effect [22] [23] [24] [25] [26] . The national authorities and public health institutions in China intended to have every Chinese citizen be vaccinated according to their vaccination priorities, and no payment from individuals would be the ideal policy [50] . But it was reported that the basic medical insurance funds in China could not afford, and might not be used for nationwide free COVID-19 vaccination, leaving detailed (national and regional) financing strategies to be considered [51] . Different pilot financing strategies have been adopted in some areas. Several provinces in China (e.g. Guangdong, Zhejiang) have rolled out free vaccinations to key and high-risk groups, while in some places such as Wuhan, people from key groups, including students going abroad, paid 234 yuan ($35.8) for each dose [48] . And in December 2020, two provinces (Jiangsu and Anhui) became the first two places to reach a deal with vaccine manufacturers [48, 49] . Vaccine producers (Sinopharm and Sinovac) would charge the government 200 yuan ($30.6) per dose [48, 49] . Based on our study, even if the total price of a full vaccination consisted of 2 doses is 400 yuan ($61.2), only about 10% of respondents will be willing to pay and accept the vaccination, which will greatly hinder the public health effect of vaccination campaign against COVID-19. Besides, uncertainties about the timing, efficacy, innocuity, safety, number of doses required, and potential side effects will affect perception and willingness to pay for the vaccination. These uncertainties (particularly safety) will also be barriers for Chinese citizens to accept COVID-19 vaccination, which may lead to the low coverage of COVID-19 vaccination. In China, there are almost no EPI vaccines for adults, so adult vaccines need to be paid 100% by individuals [26] . Very few areas have provided free flu and/or pneumococcal vaccines to the elderly, and previous studies showed that free vaccination raised the coverage of these vaccines substantially [38, 39] . And most Chinese adults did not have experiences in paying for non-EPI vaccines [52] . So if feasible, it would be simpler and most cost-effective to consider COVID-19 vaccination as a "public good" and have it financed by the central and local governments in China, given the enormous national economic and social cost of the pandemic. No fees should be charged for people in order to eliminate financial barriers to uptake. Considering the current situation that cost of essential public health programs in China (including EPI vaccination) was funded by government appropriation, while health insurance does not cover the cost of vaccination as stipulated by the national policy, COVID-19 vaccine is therefore suggested to be included into the essential public health program as one expanded program on immunization (EPI) vaccine. However, the total cost of COVID-19 vaccination still remains to be a heavy burden for governments both at the national and regional level, since it would be hard to allocate limited resources between different programs in policy-making. To address the above concern, firstly, the government could negotiate with manufacturers to reduce the vaccine price as much as possible, which ensures the affordability of COVID-19 vaccines for the general population in the demand side. This is feasible as the production cost of the vaccine would decline with the growth of scale in production and vaccination use, and manufacturers could also benefit from bulk-buying. Secondly, it is suggested that part of the cost of COVID-19 vaccination could be paid by the health insurance fund to alleviate fiscal burden, which has been adopted in other country [53] . In further consideration to better assess and finance for vaccination campaign against COVID-19 at the provincial and county level, local fiscal capacity needs to be examined carefully, and additional support from superior governments or health insurance fund is suggested to be considered [10] . Our study has several limitations. First of all, as the use of an offline survey was not feasible during the pandemic period, the online survey may limit the representativeness of the current study's sample. To address this problem, we enrolled a large sample size and used a random sampling method stratified by demographic characteristics to increase the sample diversity and representativeness. Secondly, given the hypothetical nature, the study results may differ from real practice, and some self-reported answers may lead to information bias. Thirdly, the present study did not examine the level of knowledge of immunization financing or the previous experiences of having or paying for non-EPI or children vaccines among respondents, which would affect their willingness to pay for COVID-19 vaccination. In particular, the study was carried out without any target product profile for the COVID-19 vaccine or no hypothetical information, such as the efficacy, immunity duration, number of During the COVID-19 pandemic period in China, the study reported the individuals' WTP and their preferences for financing sources, which reflected the economic valuation and affordability for future vaccination. The public stated individuals, governments and insurances could all be considered in financing COVID-19 vaccination. But to suggest an effective and optimal financing strategy in controlling and preventing the COVID-19 pandemic, the public health perspective with equal access to COVID-19 vaccination should be prioritized to ensure a high vaccination rate, with further and comprehensive information needed. Conceptualization: Hai Fang. The authors declare that they have no conflicts of interest. Tables A1, A2 and A3. [ WHO Director-General's opening remarks at the media briefing on COVID-19 -11 WHO Coronavirus Disease (COVID-19) Dashboard. Available from Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China Developing Covid-19 Vaccines at Pandemic Speed World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring. Geneva: World Health Organization Vaccines for COVID-19: perspectives, prospects, and challenges based on candidate sars, mers, and animal coronavirus vaccines DRAFT landscape of COVID-19 candidate vaccines Opinion: How a Covid-19 Vaccine Could Cost Americans Dearly How Much Will A Covid-19 Vaccine Cost Immunization Financing A Resource Guide For Advocates, Policymakers And Program Managers Dengue vaccine acceptance and willingness to pay. HUM VACC IMMUNOTHER Determinants of willingness to pay for self-paid vaccines in China Willingness to pay for an Ebola vaccine during the 2014-2016 ebola outbreak in West Africa: Results from a U.S. National sample Acceptability and Willingness-to-Pay for a Hypothetical Ebola Virus Vaccine in Nigeria. PLOS NEGLECT TROP D Assessing households' willingness to pay for an immediate pandemic influenza vaccination programme Determinants of influenza vaccine purchasing decision in the US: A conjoint analysis Pandemic influenza preparedness Framework: for the sharing of influenza viruses and access to vaccines and other benefits Pandemic Preparedness and Response -Lessons from the H1N1 Influenza of 2009 Enlightenment for the Vaccine Financing Mechanism of International Health Care System (in Chinese) Routine immunization services costs and financing in China Influenza vaccination coverage of population and the factors influencing influenza vaccination in mainland China: A meta-analysis Preferences for a COVID-19 vaccine in Australia Covid-19: Countries are learning what others paid for vaccines Covid-19 vaccines: ethical, legal and practical considerations The World Bank's COVID-19 vaccine finance plans Coronavirus vaccines strategy Protection motivation and self-efficacy: A revised theory of fear appeals and attitude change The health belief model: Explaining health behavior through expectancies. Health behavior and health education: theory, research, and practice Comparing willingness-to-pay: bidding game format versus open-ended and payment scale formats Willingness and ability to pay for health care: a selection of methods and issues The Current State of Immunization Administration in Japan Financing Immunizations in the United States The landscape of vaccines in China: history, classification, supply, and price Per capita disposable income in China Contingent assessment of the COVID-19 vaccine The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay PPP conversion factor, private consumption (LCU per international $) How does COVID-19 compare to past pandemics? Influenza and COVID-19 -similarities and differences An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China The effect of human mobility and control measures on the COVID-19 epidemic in China Attitudes about vaccines to prevent Ebola virus disease in Guinea at the end of a large Ebola epidemic: Results of a national household survey Press Conference of the Joint Prevention and Control Mechanism of the State Council Preferences for a COVID-19 vaccine in Australia The demand for a COVID-19 vaccine in Ecuador Nationwide, health insurance paid 1.232 billion yuan in medical expenses for confirmed and suspected COVID-19 patients The 140th routine press conference on prevention and control of pneumonia in COVID-19 in Beijing Government to pay 200 yuan per dose of Chinese COVID-19 inactivated vaccines Anhui starts its emergency vaccination project amid sporadic local cases in China Press Conference of the Joint Prevention and Control Mechanism of the State Council China's basic medical insurance funds cannot afford nationwide free COVID-19 vaccination: healthcare authority Status Quo and Its Influencing Factors for Four Types of Adult Vaccination in China from 2014 to 2019. Chinese Primary Health Care Ensuring COVID-19 Vaccine Affordability: Existing Mechanisms Should Not Be Overlooked Notice of the General Office of the State Council on Issuing the Reform Plan for the Division of Central and Local Financial Powers and Expenditure Responsibilities in the Medical and Health Field Jiahao Wang: Methodology, Formal analysis, Investigation, Writing -original draft, Writing -review and editing Formal analysis, Writing -original draft, Writing -review and editing Haijun Zhang: Writing -review and editing Rize Jing: Writing -review and editing Writing -review and editing Huangyufei Feng: Writing -review and editing Writing -review and editing Formal analysis, Investigation, Writingreview and editing, Funding acquisition. (The first two authors (JW and YL) contributed equally to this work Comparison of the regional distribution between respondents in the study and that in total population from 2020 China statistical yearbook a .